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Abstract
Introduction Vitamin D status measured during adulthood has
been inversely associated with breast cancer risk in some, but
not all, studies. Vitamin D has been hypothesized to prevent
breast cancer through genomic and non-genomic actions in
cell-cycle regulation.
Methods A subset (n = 21,965) of female participants from the
prospective Cancer Prevention Study-II (CPS-II) Nutrition
Cohort provided a blood sample from 1998-2001 and were
followed through 2005. We measured serum 25-hydroxyvitamin
D (25(OH)D) in 516 verified incident cases and 516 controls,
matched on birth date (± 6 months), date of blood draw (± 6
months) and race. Information on medical history, risk factors
and lifestyle was available from repeated questionnaires. We
computed multi-variable odds ratios (OR) and 95% confidence
intervals (95% CI) for the association between 25(OH)D
quintile and breast cancer risk using unconditional logistic
regression, controlling for matching factors and additional
confounders.
Results We observed no association between 25(OH)D and
breast cancer (OR = 1.09, 95% CI 0.70-1.68, P = 0.60) for the
top vs bottom quintile. Using a priori cut-points, the OR was
0.86 (95% CI 0.59-1.26), for ≥75 vs <50 nmol/L. Results were
not different when the first two years of follow-up were excluded,
or in analyses stratified by season, latitude, BMI,
postmenopausal hormone use, or by tumor grade or estrogen
receptor status.
Conclusions These results do not support an association
between adulthood serum 25(OH)D and postmenopausal
breast cancer. We cannot rule out an association with 25(OH)D
status earlier in life.
Introduction
Although breast cancer death rates have declined in recent
years, breast cancer remains the most commonly diagnosed
cancer and the second leading cause of cancer death in
women in the US. [1]. Risk factors include family history, high
breast tissue density, long menstrual history (menstrual peri-
ods that begin early and end late in life), nulliparity, late age at
first birth, use of hormone replacement therapy, regular alcohol
consumption, low physical activity, high body mass index
(BMI) and weight gain during adulthood (for postmenopausal
breast cancer). Apart from energy imbalance, dietary risk fac-
tors have not been consistently associated with risk of the dis-
ease [2].
Breast cancer rates are higher in areas of the US with lower
overall ultraviolet B radiation exposure, raising the possibility
that higher levels of vitamin D could reduce breast cancer risk
[3]. Vitamin D may regulate cell proliferation and differentiation
1,25(OH)2D: 1,25-dihydroxyvitamin D; 25(OH)D: 25-hydroxyvitamin D; BMI: body mass index; CPS-II: Cancer Prevention Study-II; CI: confidence 
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through both genomic and non-genomic effects [4]. Epidemi-
ologic studies have observed lower breast cancer risk with
greater self-reported [5] and measured [6] sun exposure. The
association between dietary and supplemental intake of
vitamin D with breast cancer risk has been inconsistent [7],
potentially because typical doses of vitamin D intake have
comparatively less impact on vitamin D status than ultraviolet
B exposure, and because of measurement error in nutrition
assessment. Circulating 25-hydroxyvitamin D (25(OH)D)
reflects an input of vitamin D from both sun exposure and diet
over the preceding several weeks, and thus represents an inte-
grated measure of vitamin D status. This metabolite is thought
to be relevant because it provides substrate for tissue-specific
synthesis of the active form of vitamin D (1,25-dihydroxyvita-
min D (1,25(OH)2D)), the natural ligand for the nuclear vitamin
D receptor. Although three case-control studies reported an
inverse relation between circulating 25(OH)D and breast can-
cer risk [8-10], results from three nested case-control studies
where blood was collected prior to diagnosis were less con-
sistent [11-13].
If vitamin D status is associated with a lower risk of breast can-
cer, this would represent an easily modifiable risk factor. To
contribute to the limited and inconsistent prospective data on
this topic of important public health interest, we examined cir-
culating 25(OH)D concentrations in a nested case-control
study of over 500 postmenopausal breast cancer cases and
their matched controls from the Cancer Prevention Study-II
(CPS-II).
Materials and methods
Study population
Women in this analysis were participants in the CPS-II Nutri-
tion Cohort, a prospective study of cancer incidence among
men and women from 21 states in the US, established by the
American Cancer Society in 1992 [14]. At enrollment, 86,404
men and 97,788 women completed a 10-page, self-adminis-
tered questionnaire on medical, dietary, reproductive, and life-
style variables. Beginning in 1997, follow-up questionnaires
were sent to cohort members every two years to update expo-
sure information and to ascertain newly diagnosed cancers. All
aspects of the CPS-II cohort were approved by the Emory Uni-
versity (Atlanta, GA, USA) Institutional Review Board.
Breast cancer nested case-control study
From June 1998 to June 2001, blood specimens were col-
lected from 21,965 women in the Nutrition Cohort who lived
near a major collaborating hospital or medical clinic in their
community, as described in detail elsewhere [14]. All partici-
pants completed a brief questionnaire and provided informed
consent at the time of blood draw. We collected a maximum
of 43 mL of nonfasting whole blood from each participant
drawn in two 15 mL tubes containing the anticoagulant ethyl-
enediamine tetraacetic acid and a 13 mL serum separator
tube. Hospital staff centrifuged the serum separator tubes to
separate serum from cellular blood components prior to ship-
ping, and all samples were then shipped in foam containers
with coolant packs overnight by Express Mail to a central
repository in Rockville, Maryland. Shipments of blood from the
field were received, unpacked, aliquoted, and frozen in liquid
nitrogen vapor phase at approximately -130°C for long-term
storage [14].
Eligible cases included women who reported a new diagnosis
of breast cancer on a biennial CPS-II Nutrition Cohort Survey
between the date of their blood draw and 30 June, 2005 (n =
514) or who did not report an incident breast cancer but for
whom fatal breast cancer was identified through linkage with
the National Death Index [16] (n = 2). We asked women
reporting a diagnosis for permission to review their medical
records to confirm their diagnosis. If medical records were not
available, we contacted state cancer registries. Previous pilot
work in this cohort found that the sensitivity of self-reported
breast cancer was 91% [15] suggesting we successfully
ascertained incident breast cancer cases in the cohort.
We initially identified a total of 535 breast cancers diagnosed
after the date of blood draw. We excluded women who were
pre- or peri-menopausal (n = 3) at baseline, those with no
appropriate match (n = 1), women with one or less vial of
serum (n = 14), and one woman with an extreme 25(OH)D
level (more than three standard deviations above the mean).
The analysis is based on 516 cases and on an equal number
of matched controls, aged 47 to 85 years at baseline. The
duration of follow-up between the date of blood draw and
breast cancer diagnosis ranged from less than 1 month to 6.9
years.
We documented the estrogen receptor (ER) and progester-
one receptor (PR) status of the tumors from medical record
reports and through state cancer registries, when available.
Information on ER and PR status was available for 76% and
73% of cases, respectively.
Control selection
Each control was individually matched to a case on birth date
(± 6 months), race/ethnicity (Caucasian, African-American,
other/unknown), and date of blood collection (± 6 months).
We randomly selected one postmenopausal female control
who had provided a blood sample and was cancer free
(except for non-melanoma skin cancer) at the date of the diag-
nosis of the case. For two cases of 'other' race, an appropri-
ately matched control was not available, and they were
matched to a Caucasian control.
Vitamin D assays
Laboratory analyses were conducted at Heartland Assays, Inc
(Ames, IA, USA). Case-control pairs were analyzed in the
same batch in no particular order. A direct, competitive chemi-
luminescence immunoassay using the DiaSorin LIAISON plat-Available online http://breast-cancer-research.com/content/11/4/R64
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form, as described in detail elsewhere [17], was used to
quantitate 25(OH)D levels.
Quality control
An average of five quality control samples were included in
each batch of 100 samples. These quality control samples
were from four separate sources: a pooled sample of non-mul-
tivitamin users, a pooled sample of multivitamin users, and two
individual CPS-II Nutrition Cohort participants.
Coefficients of variation (CV) for duplicate serum aliquots
included in all laboratory sample batches were calculated for
each of the four quality control samples, and ranged from 6.4
to 8.8%. Intra-batch and inter-batch CVs were 5.4% and
8.1%, respectively.
Measurement of covariates
Information on breast cancer risk factors and potential con-
founders was ascertained from responses to biennial ques-
tionnaires from the CPS-II cohort. For the current analysis, we
obtained information on current BMI, date of blood draw, and
use of individual vitamin D supplements from the brief ques-
tionnaire completed at blood draw. Information on reproduc-
tive risk factors, history of benign breast disease, family history
and education was assessed on earlier questionnaires. Other
variables, including alcohol use, postmenopausal hormone
use, diet, recreational physical activity and zip code (for lati-
tude) were collected from the comprehensive 1999 question-
naire. For these variables, 24 cases (5%) completed the
questionnaire after diagnosis of breast cancer. Sensitivity anal-
yses removing these cases and their controls did not change
the risk estimates.
Data analysis
Circulating 25(OH)D (nmol/L) was normally distributed and
was not improved with log transformation; thus, we used
untransformed values. We divided participants into quintiles
based on the distribution of serum 25(OH)D in the control
group. We observed the expected differences in 25(OH)D
concentrations by season of blood draw: mean levels (±
standard deviation) were 49.1 (± 21.2) in Winter (December
to February), 53.7 (± 25.1) in Spring (March to May), 58.1 (±
22.2) in Summer (June to August) and 59.5 (± 20.3) in Fall
(September to November). For stratified analyses, we classi-
fied season according to two general seasons: a 'warm' sea-
son (June to November) and a 'cool' season (December to
May). Independent correlates of 25(OH)D among controls in
our study were evaluated using linear regression models.
Our primary statistical approach used unconditional logistic
regression to estimate the odds ratio (OR) and 95% confi-
dence intervals (CI) for risk of cancer comparing quintiles 2 to
5 with the lowest quintile, to preserve statistical power when
conducting stratified analyses on factors that were not
matched by design. In sensitivity analyses, we also conducted
conditional logistic regression on main effects models and
results were similar. We first assessed the relation between
serum 25(OH)D and breast cancer risk adjusting only for
matching factors (date of birth ± six months, date of serum col-
lection ± six months, race (white, other)).
In addition to controlling for matching factors, we included as
covariates those factors that were correlated with serum
25(OH)D concentrations and/or related to breast cancer risk
in this sample. These included: season of serum collection
(Winter/Spring/Summer/Fall); weight change since age 18
years (lost >5 kg, lost or gained <5 kg, gained 5 to <10, 10 to
<20, 20 to <30, and 30+ kg, and missing data); body mass
index (<22.5, 22.5 to <25.0, 25.0 to <30 (and missing data),
30.0+), and combinations of number of live births (nulliparous,
1 to 2, 3+) and age of mother at first birth (<25 or ≥25).
Adjustment for alcohol consumption (non-drinker, <1 drink/
day, 1+ drink/day, missing data); recreational physical activity
in metabolic equivalents (MET) hours per week (quartiles);
family history of breast cancer (yes, no); history of benign
breast disease (yes, no); age at menarche (<12, 12, 13 (and
missing data), >13 years); age at menopause (<45, 45-<50,
50-<54, 54+ years), and postmenopausal hormone use
(never, former, current) did not change the effect estimates
and therefore were not included. To test for trend, we created
a continuous variable consisting of the median 25(OH)D value
from each quintile, and included this variable in the regression
model.
We additionally examined the association between 25(OH)D
and breast cancer risk using a priori cut-points of less than 50
nmol/L as deficiency (referent), 50 to less than 75 nmol/L as
'insufficient', and 75+ nmol/L as 'adequate' [18]. We exam-
ined the possibility of a non-linear relation between circulating
25(OH)D and breast cancer risk using restricted cubic splines
[19]. The linearity of the association between 25(OH)D and
breast cancer risk was tested using the likelihood ratio test,
comparing the model with only the linear term to the model
with the linear and the cubic spline terms.
We conducted stratified analyses comparing breast cancer
risk across tertiles of 25(OH)D concentration within strata of
postmenopausal hormone use (never and ever use), BMI (<25
and ≥25 kg/m2), time of year of blood draw ('warm' and 'cool'
seasons), latitude (above and ≤37°), tertile of total calcium
intake, multivitamin supplement use (assessed in 1999) and
use of individual vitamin D supplements (yes, no) reported at
blood draw. Interaction terms were cross-product terms of the
tertile measure (0, 1, 2, in continuous form) and dummy varia-
bles for potential effect modifiers. Multiplicative interactions
were evaluated using the likelihood ratio test.
We conducted sensitivity analyses excluding cases diag-
nosed during the first two years of follow-up, and using sea-
son-specific 25(OH)D quintile cut-points [20]. We alsoBreast Cancer Research    Vol 11 No 4    McCullough et al.
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evaluated the association between 25(OH)D and breast can-
cer according to ER status of the tumor, and according to
tumor invasiveness (in situ, local, regional/distant). All
statistical analyses were conducted using SASv.9.2 (SAS
Institute, Inc., Cary, NC, USA).
Results
Characteristics of the postmenopausal breast cancer cases
and controls are provided in Table 1. The age and race of par-
ticipants were similar, as expected based on matching criteria.
Although the mean BMI was not different between cases and
controls, breast cancer cases had gained more weight since
age 18 compared with controls. A greater percentage of
cases reported a family history of breast cancer, a personal
history of benign breast disease, and a later age at meno-
pause. Controls had more children earlier in life compared with
cases. There was no difference in the percentage of cases and
controls currently or formerly taking postmenopausal hor-
mones. A slightly higher (non-significant) percentage of cases
consumed more than one alcoholic drink per day. Recreational
physical activity and use of nutritional supplements were not
appreciably different between cases and controls.
Several factors predicted circulating 25(OH)D among con-
trols (results not shown). Winter season predicted significantly
lower 25(OH)D concentrations compared with Summer. Cur-
rent BMI and weight gain each individually predicted
25(OH)D, but when considered simultaneously, current BMI
was the stronger predictor. Recreational physical activity was
associated with significantly higher concentrations, likely due
to greater sunlight exposure during outdoor exercise. Total
vitamin D intake (which was not considered as a confounder
due to potential over-control) was a statistically significant pre-
dictor of 25(OH)D in univariate and multivariate models. An
increment of 800 IU vitamin D corresponded to a 16 nmol/L
higher circulating 25(OH)D in both models (not shown).
Table 2 presents the OR and 95% CI for the association
between quintile of 25(OH)D and postmenopausal breast
cancer risk. Compared with women in the lowest 25(OH)D
quintile (<36.7 nmol/L), the OR for women in the highest quin-
tile (>73.2 nmol/L) was 1.09 (0.70 to 1.68; P = 0.6). A cubic
spline graph (Figure 1) illustrates this association with knots
forced at quintile cut-points. An apparent inverse U-shaped
association was not statistically significantly non-linear (P =
0.54). Results were similar when 227 cases diagnosed in the
first two years after blood draw were excluded (OR for fifth vs
first quintile = 1.04, 95% CI 0.62 to 1.75, not shown). Results
using season-specific 25(OH)D cut-points were also similar
(OR for fifth vs first quintile = 1.13, 95th CI 0.74-1.72). In sub-
analyses using absolute cut-points of 75 or more vs less than
50 nmol/L, the ORs remained null for all cases (0.86, 95% CI
0.59 to 1.26; P = 0.7).
Associations by ER status and tumor subtype were examined
using tertiles of 25(OH)D concentration to allow comparison
among groups with smaller numbers (Table 2). There were no
differences by ER status of the tumor, and addition of PR sta-
tus combined with ER status did not meaningfully affect the
results. Likewise, there were no differences in results when
tumors were classified as in situ, localized, or regional/distant.
In sub-analyses using absolute cut-points of 75 or more vs
less than 50 nmol/L; ORs (± 95 CI) were: ER+, OR = 0.86,
95% CI 0.56 to 1.32, P = 0.8; ER-, OR = 0.90, 95% CI 0.35
to 2.30, P = 1.0; in situ, OR = 0.64, 95% CI 0.32 to 1.30, P
= 0.3; localized, OR = 1.16, 95% CI 0.76 to 1.78, P = 0.3;
regional and distant, OR = 0.39, 95% CI 0.16 to 0.92, P =
0.08. Thus, when using established cut-points, individuals
who had sufficient vs. deficient levels were at borderline lower
risk for regional/distant tumors. When modeled by each 10
nmol/L change in 25(OH)D, the multivariate-adjusted ORs
and 95% CIs were as follows: all cases (1.01, 0.95 to 1.07);
ER+ cases (1.02, 0.96 to 1.09); ER- cases (0.91, 0.78 to
1.06);  in situ cases (0.99, 0.90 to 1.09); localized cases
(1.04, 0.97 to 1.10) and regional/distant cases (0.93, 0.83 to
1.05).
The association between 25(OH)D and breast cancer risk did
not vary by history of postmenopausal hormonal therapy, BMI,
weight gain, 'warm' and 'cool' season of blood draw, or cal-
cium intake. A significant interaction was observed by latitude:
the OR among women living at 37° or more latitude who were
in the top tertile of 25(OH)D (64 nmol/L+) vs bottom tertile
(<46 nmol/L) was 0.35 (95% CI 0.17 to 0.73), vs OR = 1.07
(95% CI 0.59 to 1.95) among women living at <37° (P inter-
action = 0.003). The relation did not vary by use of vitamin D-
containing multivitamin supplements (measured in 1999), but
a significant interaction was observed for use of individual vita-
min D supplements (yes, no) at blood draw: among women
who reported not using vitamin D supplements, the OR for the
top vs bottom tertile was 0.82 (95% CI 0.53 to 1.27), whereas
among current users it was 1.82 (0.61 to 5.39; P interaction
= 0.047).
Discussion
In this nested case-control study of mostly Caucasian women,
serum 25(OH)D concentrations assessed up to six years prior
to diagnosis were not associated with risk of postmenopausal
breast cancer. This finding did not change when we excluded
cases occurring in the first two years after blood draw, and
were not significantly different in analyses stratified by BMI,
postmenopausal hormone use, season of blood draw, calcium
intake, or multivitamin use. Likewise, 25(OH)D concentrations
were not significantly associated with cancer subgroups
defined on the basis of ER/PR status, or tumor stage/grade.
Our findings contribute to the relatively few prospective stud-
ies published on this topic [11-13]. In a nested case-control
analysis of 701 cases and 724 controls from the Nurses'Available online http://breast-cancer-research.com/content/11/4/R64
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Table 1
Baseline characteristics in cases and controls, CPS II Nutrition Cohort Women (1999 to 2005)*
Characteristic Cases (n = 516) Controls (n = 516) P value‡‡
Mean (SD)
Age at serum collection (year) 69.5 (5.9) 69.6 (5.8) 0.7
Plasma 25(OH)D (nmol/L) 56.5 (22.0) 56.2 (22.2) 0.8
Latitude (degree) 39.0 (4.7) 39.3 (4.8) 0.2
BMI at blood collection (kg/m2) 25.9 (4.9) 25.8 (4.8) 0.9
Weight gain since age 18 (kg) 14.1 (15.5) 11.1 (18.3) 0.006
Exercise METS† 15.4 (13.8) 15.6 (14.7) 0.9
Age at menarche (years) 12.7 (1.5) 12.7 (1.4) 0.6
Age at menopause (years) 48.6 (6.1) 47.8 (6.0) 0.03
Percentage (%)
Family history of breast cancer 23.6 16.9 0.007
History of benign breast disease 33.9 27.5 0.01
Race
White 96.7 97.1 0.7
Other (Black/Hispanic/Oriental) 3.3 2.9
College graduate 24.2 23.4 0.5
Parity and age at first birth
Nulliparous 9.1 8.5 0.006
<25, 1 to 2 live births 13.2 12.4
25+, 1 to 2 live births 22.5 14.7
<25, 3+ live births 35.3 45.0
25+, 3+ live births 20.0 19.4
Postmenopausal hormone use
Never 22.1 25.4 0.4
Former 58.1 53.1
Current 16.1 16.7
Season of blood collection
Dec to Feb 15.1 18.2 0.1
Mar to May 18.8 17.4
Jun to Aug 35.1 29.5
Sep to Nov 31.0 34.9
Alcohol intake (≥ 1 drink/day) 21.3 16.1 0.1
Multivitamin use containing vitamin D‡
Not current user 30.8 34.9 0.6
Current user 63.6 59.6
Calcium supplement use
Not current user 32.4 32.9 0.5
Current user 59.9 57.3Breast Cancer Research    Vol 11 No 4    McCullough et al.
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Health Study, Bertone and colleagues [11] observed a border-
line 27% lower relative risk of breast cancer comparing
women in the top vs bottom 25(OH)D quintile (P = 0.06). In
contrast, among 1005 postmenopausal cases and 1005
controls from the Prostate, Lung, Colorectal and Ovarian Can-
cer Screening Trial [13], no association between prediagnos-
tic 25(OH)D and breast cancer risk was found (OR = 1.04,
95% CI 0.75 to 1.45), comparing top (≥84 nmol/L) to bottom
(<45.8 nmol/L) quintile. A prospective analysis from the
NHANES study [12] reported a relative risk for fatal breast
cancer (n = 28 cases) among women with 62.5 nmol/L or
higher vs less than 62.5 nmol/L circulating 25(OH)D of 0.28
(95% CI 0.08 to 0.93; P trend of continuous 25(OH)D = 0.76)
[12]. All three published case-control studies [8-10] reported
statistically significant inverse associations between circulat-
ing 25(OH)D and breast cancer risk. However, because blood
was drawn after cancer diagnosis, it is possible that cancer
diagnosis may have influenced circulating 25(OH)D through
treatment or behavioral changes. Finally, reports from two ran-
domized controlled trials of vitamin D and/or calcium supple-
mentation were indeterminate [21,22]. A seven-year
randomized trial observed no difference in breast cancer risk
for women receiving 400 IU vs placebo [21], but the interven-
tion study dose was relatively low and a high percentage of
women in the control group began taking supplements during
the trial. The other study found a lower risk of overall cancer
with the use of 1100 IU vitamin D in a secondary analysis from
an osteoporosis trial [22], but there were too few breast can-
cers to examine this outcome separately.
Our study did not indicate the existence of a threshold for a
protective association with breast cancer with circulating
25(OH)D, which has been hypothesized by some [23]. In the
Nurses' Health Study, risk was lower starting at an approxi-
mate threshold of 70 to 80 nmol/L (different cut-points were
employed by batch) [11]. Similar to our findings, Freedman
and colleagues [13] found no association overall, with a non-
significant slightly higher breast cancer risk in the middle quan-
tiles of circulating 25(OH)D. Because the shape of the
25(OH)D - breast cancer association in the current study indi-
cated a lower risk at both ends of the distribution, ORs were
sensitive to the cut-points used. For example, in analyses using
quintiles, 25(OH)D concentrations in the middle quantiles
were associated with slightly higher risk. However, when we
used a priori cut-points for deficiency, insufficiency and suffi-
ciency [18], which resulted in shifting the referent group to
higher 25(OH)D concentrations, there was no suggestion of
increased risk in any category.
Body fat and weight gain were moderate negative confound-
ers in our study (with the net effect of raising the OR when
added to either the age-adjusted model or multivariate mod-
els), and BMI independently predicted circulating 25(OH)D.
Body fat is a large storage reservoir for 25-OH-vitamin D, and
lower circulating 25(OH)D in obese individuals is thought to
be related to greater uptake into fat tissues, rather than lower
sun exposure or less effective vitamin D synthesis [24]. In the
Women's Health Initiative [21], baseline 25(OH)D was asso-
ciated with a significantly lower risk of breast cancer, until
models were further adjusted for BMI and physical activity.
Vitamin D supplement use§
Not current user 54.1 53.7 0.9
Current user 16.1 16.9
Mean (SD)
Dietary variables#
Total calcium (mg/day) 1358.0 (565.2) 1293.7 (576.6) 0.08
Dietary calcium (mg/day) 777.0 (285.3) 768.6 (283.0) 0.6
Supplemental calcium (mg/day) 581.0 (504.3) 515.0 9493.4) 0.08
Total vitamin D (IU/day) 439.5 (243.6) 415.0 (239.7) 0.1
Dietary vitamin D (IU/day) 192.0 (105.3) 187.6 (96.1) 0.5
* Standardized to age distribution of the study population.
† Metabolic equivalent of task (METS) are defined for each type of exercise-related physical activity as a multiple of metabolic equivalent of sitting 
quietly for one hour.
‡ Reported on the 1999 questionnaire.
§ Reported at blood collection.
# All dietary variables are adjusted for energy intake which was estimated from the 1992 brief Block Food Frequency Questionnaire (FFQ).
‡‡†† P values for categorical variables are based on the chi-squared test and P values for continuous variables are based on the t-test for difference 
of means.
25(OH)D = 25-hydroxyvitamin D; BMI = body mass index; CPS-II = Cancer Prevention Study-II; SD = standard deviation.
Table 1 (Continued)
Baseline characteristics in cases and controls, CPS II Nutrition Cohort Women (1999 to 2005)*Available online http://breast-cancer-research.com/content/11/4/R64
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Studies of vitamin D and cancer risk need to carefully examine
and control for potential confounding by obesity.
We found that 25(OH)D-breast cancer associations were
modified by individual vitamin D supplement use at blood
draw, with an inverse association among non-current vitamin D
supplement users and a positive association among current
supplement users (P interaction = 0.047). Reasons for this
apparent interaction are unclear. It is possible that the source
of vitamin D may be important. For example, at any given level
of serum 25(OH)D, non-supplement users obtain a higher pro-
portion of their vitamin D from cutaneous synthesis, and/or
greater intake of fortified milk or fish than do supplement users.
Vitamin D in the diet is strongly correlated with dietary calcium,
which also may play a role in preventing breast carcinogenesis
[25,26]. We also observed a significant inverse association
between 25(OH)D and breast cancer risk among women liv-
ing in northern (>37°), but not southern (≤37°) latitudes. Over
95% of women in this analysis living in the north were born in
the north, whereas 64% of the women living at 37° or lower lat-
itude were born in the south. It is possible that low 25(OH)D
concentrations among women living in the north correlate bet-
ter with chronically low concentrations. However, both of
these interactions may also be due to chance.
A potential explanation for our null findings is that we missed
the etiologically relevant time frame of vitamin D exposure for
breast carcinogenesis. Several studies observed stronger
inverse associations between greater intake of vitamin D and/
or calcium in relation to mammographic density or breast can-
cer among premenopausal women [9,25,27-29] than post-
menopausal women. In addition, self-reported sun exposure
earlier in life was more strongly associated with postmenopau-
sal breast cancer than sun exposure later in life [30]. We were
unable to examine the relation between 25(OH)D and premen-
opausal breast cancer, or earlier life vitamin D exposure in rela-
tion to postmenopausal breast cancer. Additional limitations
include a lower range of circulating 25(OH)D compared with
some other studies [8,11,13], limiting our ability to examine
higher cut-points of 25(OH)D status. This study also had a rel-
atively small sample size, particularly when examining associa-
tions by tumor receptor status and subtype.
An advantage of this study is the use of an objective biomarker
of vitamin D status, which reflects the integration of dietary and
supplemental vitamin D intake as well as cutaneous synthesis.
It is possible, however, that our single measure of 25(OH)D
did not correctly classify women according to their usual, year-
round vitamin D status. Circulating 25(OH)D reflects exposure
to sun and diet from approximately the prior two months. Fur-
ther, 25(OH)D fluctuates according to season of the year. To
minimize this extraneous source of variation, we controlled for
season of blood draw, and in sensitivity analyses, we used
season-specific cut-points. Analyses stratified by season of
blood draw were not statistically different.
Conclusions
Our findings do not support an association between adult-
hood 25(OH)D status and postmenopausal breast cancer
risk. Future studies with the ability to examine a wider distribu-
tion of 25(OH)D, vitamin D status earlier in life, and with
greater statistical power to examine tumor subtypes and stage
would add importantly to the literature.
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Restricted cubic spline showing the fully adjusted associations  between serum 25(OH)D levels and breast cancer risk in 1032 partici- pants in the Cancer Prevention Study-II Nutrition Cohort Restricted cubic spline showing the fully adjusted associations 
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pants in the Cancer Prevention Study-II Nutrition Cohort. The reference 
value is less than 36.7 nmol/L. The knots are defined by the quintile cut 
points for 25-hydroxyvitamin D (25(OH)D) and are 36.7, 49.8, 60.8, 
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Table 2
Odds ratio (OR) and 95% confidence interval (CI) between 25(OH)D levels and breast cancer risk, CPS II Nutrition Cohort women
Quintiles of serum 25(OH)D concentration (nmol/L) P for trend‡
<36.7 36.7-<49.8 49.8-<60.8 60.8-<73.2 73.2+
All cases (n) 89 115 99 118 95
Controls (n) 104 102 105 102 103
OR (95% CI)* 1.00 (-) 1.31 (0.88-1.94) 1.11 (0.74-1.66) 1.35 (0.91-2.01) 1.07 (0.71-1.61) 0.8
OR (95%CI)† 1.00 (-) 1.29 (0.86-1.94) 1.14 (0.75-1.72) 1.44 (0.96-2.18) 1.09 (0.70-1.68) 0.6
Tertiles of serum 25(OH)D concentration (nmol/L) P for trend‡
<45.9 45.9-<64.2 64.2+
ER+ cases (n) 102 120 120
Controls (n) 177 160 179
OR (95% CI)* 1.00 (-) 1.32 (0.94-1.87) 1.16 (0.82-1.63) 0.4
OR (95%CI)† 1.00 (-) 1.32 (0.93-1.88) 1.15 (0.80-1.65) 0.5
ER- cases (n) 17 16 16
Controls (n) 177 160 179
OR (95% CI)* 1.00 (-) 1.02 (0.49-2.12) 0.90 (0.44-1.87) 0.8
OR (95%CI)†
1.00 (-) 1.03 (0.48-2.19) 0.95 (0.43-2.06) 0.9
In situ cases (n)§ 34 39 30
Controls (n) 177 160 179
OR (95% CI)* 1.00 (-) 1.29 (0.77-2.16) 0.89 (0.52-1.54) 0.7
OR (95%CI)† 1.00 (-) 1.23 (0.72-2.09) 0.87 (0.49-1.55) 0.7
Localized cases (n)§ 90 114 114
Controls (n) 177 160 179
OR (95% CI)* 1.00 (-) 1.44 (1.01-2.06) 1.25 (0.88-1.79) 0.2
OR (95%CI)† 1.00 (-) 1.45 (1.01-2.09) 1.30 (0.90-1.89) 0.2
Regional/Distant Cases (n)§ 35 25 28
Controls (n) 177 160 179
OR (95% CI)* 1.00 (-) 0.79 (0.45-1.38) 0.79 (0.46-1.37) 0.4
OR (95%CI)† 1.00 (-) 0.78 (0.43-1.41) 0.75 (0.41-1.37) 0.3
* Unconditional logistic regression adjusted for birth year, year of blood draw, race, and season.
† Unconditional logistic regression adjusted for birth year, year of blood draw, race, season, parity and age at first birth, body mass index at blood 
collection and weight change from age 18 years to blood collection.
‡ P value for trend is calculated using the median for each category and modeled as a continuous variable.
§ Definition of cases based on Surveillance Epidemiology and End Results (SEER) summary staging.
25(OH)D = 25-hydroxyvitamin D; CPS-II = Cancer Prevention Study-II; CI = confidence interval; ER = estrogen receptor; OR = odds ratio.Available online http://breast-cancer-research.com/content/11/4/R64
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